Nanohale AG (ETR:FYB)

BRIEF

published on 08/07/2024 at 06:55, 1 year 5 months ago

Formycon Announces Conference Call on 2024 Half-Year Results and Investor Conference Participation

Conference Call Investor Conferences Formycon AG Half-year Results Financial Outlook
PRESS RELEASE

published on 08/07/2024 at 06:50, 1 year 5 months ago

Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
Formycon schedules conference call on 2024 half-year results and confirms participation in investor conferences. Details on webcast and management presentations

Financial Results Conference Call Investor Conferences Biosimilars Formycon
BRIEF

published on 08/06/2024 at 12:45, 1 year 5 months ago

Formycon AG Increases 2024 Fiscal Year Outlook

Adjusted EBITDA Working Capital Fiscal Year 2024 Formycon AG Biosimilars
PRESS RELEASE

published on 08/06/2024 at 12:40, 1 year 5 months ago

EQS-Adhoc: Formycon AG increases its outlook for the 2024 fiscal year
Formycon AG increases its 2024 fiscal year outlook based on positive Lucentis biosimilar performance, adjusting EBITDA and working capital forecasts

Adjusted EBITDA Working Capital Formycon AG 2024 Fiscal Year Lucentis Biosimilar
BRIEF

published on 07/30/2024 at 06:55, 1 year 6 months ago

Formycon Begins Phase III Clinical Trial for Keytruda® Biosimilar FYB206

Clinical Trials Biosimilar Formycon FYB206 Keytruda
PRESS RELEASE

published on 07/30/2024 at 06:50, 1 year 6 months ago

Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
Formycon AG initiates Phase III clinical trial for FYB206, a Keytruda biosimilar, in NSCLC patients in Eastern Europe and Southeast Asia. Study aims to compare safety and efficacy with Keytruda

Formycon AG NSCLC Phase III Trial FYB206 Keytruda Biosimilar
BRIEF

published on 07/26/2024 at 12:05, 1 year 6 months ago

Formycon and Fresenius Kabi Receive Positive CHMP Opinion for FYB202 (Ustekinumab)

Biosimilar Formycon Fresenius Kabi FYB202 CHMP Opinion
PRESS RELEASE

published on 07/26/2024 at 12:00, 1 year 6 months ago

Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 biosimilar candidate to Stelara. Approval expected in early Q4 2024. Biosimilars boost healthcare access & reduce costs globally

Biosimilar Formycon Fresenius Kabi FYB202 CHMP Opinion
BRIEF

published on 07/26/2024 at 10:59, 1 year 6 months ago

FYB202 Biosimilar to Stelara Receives Positive CHMP Opinion from EMA

Biosimilar Formycon FYB202 CHMP EMA
PRESS RELEASE

published on 07/26/2024 at 10:54, 1 year 6 months ago

EQS-Adhoc: Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
Formycon AG's biosimilar candidate FYB202 (Ustekinumab) for Stelara® receives a positive opinion from EMA's CHMP, recommended for EU approval for treating severe inflammatory diseases

Formycon AG Biosimilar FYB202 CHMP EMA

Published on 01/30/2026 at 14:00, 4 hours 57 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 10 hours 22 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 10 hours 57 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 16 hours 42 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 18 hours 57 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

Published on 01/30/2026 at 18:31, 25 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/30/2026 at 18:30, 26 minutes ago

HOL-Holdings in Company
Published on 01/30/2026 at 18:23, 33 minutes ago

TVR-Total Voting Rights
Published on 01/30/2026 at 18:17, 39 minutes ago

POS-Transaction in Own Shares
Published on 01/30/2026 at 18:17, 39 minutes ago

Holding(s) in Company

View all EQS

Published on 01/30/2026 at 17:45, 1 hour 12 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 10 hours 57 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 1 hour ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 1 hour ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News